Reviews on recent clinical trials最新文献

{"title":"Ethics Committees Selection in Italy under EU Regulation 536/2014: A Three-year Governance Analysis.","authors":"Giulia Pierfelice, Eleonora De Paola, Diego Alejandro Dri, Raffaella Maione, Paola Aita, Fabrizio Galliccia, Sandra Petraglia, Giulia Piazza, Anna Minarini","doi":"10.2174/0115748871477660260504043223","DOIUrl":"https://doi.org/10.2174/0115748871477660260504043223","url":null,"abstract":"<p><strong>Introduction: </strong>The implementation of Regulation (EU) No. 536/2014 (CTR) introduced a reformed clinical trial governance system in Italy, based on a single national ethics opinion, replacing the previous decentralized model. This transition has raised important questions regarding how sponsors orient their choice of Ethics Committees (ECs) within the new regulatory framework. The aim of this study is to evaluate geographical trends in sponsor-proposed ECs for clinical trials in Italy between January 2022 and January 2025, and to examine their association with therapeutic area, trial phase, and population characteristics.</p><p><strong>Materials and methods: </strong>We conducted a retrospective three-year nationwide analysis based on data from the Italian Medicines Agency (AIFA) and the Clinical Trials Information System (CTIS). Adopting a longitudinal approach, descriptive and comparative evaluations were performed.</p><p><strong>Results: </strong>A total of 1,462 Clinical Trials (CTs) were identified, of which 1,135 (77.8%) involved sponsor-proposed Ethics Committees (ECs), including both legacy ECs operating under Directive 2001/20/EC and Territorial Ethics Committees (TECs) active since June 2023. A marked geographical imbalance emerged in sponsor proposals: 60.2% targeted ECs located in Northern Italy, 26.4% in Central Italy, and 13.4% in Southern Italy and the Islands, with additional intra-regional disparities. Non-commercial sponsors often chose TECs within their own region (64.7%), frequently within the same institution.</p><p><strong>Discussion: </strong>The results show a concentration of sponsor-proposed ECs in Northern Italy, together with marked intra-regional concentration patterns in regions hosting multiple ECs. The distribution of proposals also indicates that non-commercial sponsors frequently select TECs located within their own region and institution. In the most recent part of the observation period, a modest increase in proposals to Central TECs has been recorded.</p><p><strong>Conclusions: </strong>This nationwide analysis provides a descriptive overview of sponsor-driven EC selection in Italy under the CTR, identifying inter-regional and intra-regional imbalances. While some changes in sponsor behavior are observed in the latest data, continued monitoring over time is required. The observed patterns may be potentially influenced by contextual and organisational factors, as well as by additional variables not directly assessed in the analysis. Future studies incorporating these variables will be important to confirm whether the trends identified here persist over time and to better clarify the factors contributing to their distribution.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147942991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lifileucel: Shedding Light on a New Treatment for Advanced Melanoma.","authors":"Ariana Genovese, Andrea Ashchi Lachapelle, Andrew Ashchi, Kelli Corona, Lauren Carpenter, Andres Valdes, Ashish Kumar, Jessica Huston","doi":"10.2174/0115748871444837260417095431","DOIUrl":"https://doi.org/10.2174/0115748871444837260417095431","url":null,"abstract":"<p><p>Lifileucel is a tumor-derived autologous T cell therapy approved for unresectable or metastatic melanoma in adults. This article discusses 10 clinical studies on lifileucel for the treatment of advanced melanoma. The phase II study data available evaluated the safety and efficacy of lifileucel in a global, multicenter study involving adult patients with unresectable or metastatic melanoma who had previously received systemic therapies, including a PD-1 blocking antibody and, if applicable, BRAF and MEK inhibitors. Among 73 patients treated with the recommended dose, the objective response rate was 31.5%, with 4.1% achieving a complete response and 27.4% a partial response. Of the responders, 56.5%, 47.8%, and 43.5% maintained their responses without progression or death at 6, 9, and 12 months, respectively. The most common adverse events seen in clinical studies include thrombocytopenia, anemia, and febrile neutropenia. Additional studies are underway to provide further data on the use of lifileucel as a safe and effective intravenous treatment option for unresectable or metastatic melanoma. This article reviews the published data encompassing the preliminary development, pharmacology, efficacy, and safety of lifileucel.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147943030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hydrogel-based Advances in Dermatological Therapy: Insights from Patents and Clinical Research.","authors":"Monika Verma, Neha Yadav, Smita Narwal, Nisha Grewal, Ashwani K Dhingra, Bhawna Chopra","doi":"10.2174/0115748871449923260330194138","DOIUrl":"https://doi.org/10.2174/0115748871449923260330194138","url":null,"abstract":"<p><p>Treating skin conditions, chronic wounds, and soft tissue injuries remains a major challenge in contemporary healthcare, with substantial financial costs and impacts on patients' quality of life. Hydrogels comprise interconnected networks of hydrophilic polymers characterized by high water content. They have emerged as a promising class of biomaterials in dermatology due to their structural similarity to the extracellular matrix, excellent biocompatibility, and adjustable mechanical properties. With a focus on wound healing, skin tissue engineering, the treatment of chronic inflammatory illnesses (such as acne, psoriasis, and eczema), and cosmetic and anti-aging procedures, this review provides a thorough overview of the development and application of hydrogel-based systems in dermatology. This review discusses the functional characteristics, therapeutic action, and clinical advantages of various formulations-including natural, synthetic, hybrid, and nanocomposite hydrogels. Additionally, a review of current patents and clinical studies provides an example of the new hydrogel technology landscape, which includes bioactive and smart hydrogels as well as multifunctional composites for enhanced skin regeneration and controlled drug delivery. Combining hydrogels with innovative technologies such as nanomaterials, 3D bioprinting, and responsive biomaterials further underscores the revolutionary potential in dermatological therapy. The research suggests that hydrogel-based methods are redefining the future of skin regeneration, repair, and cosmetic treatment by offering improved aesthetic outcomes, quicker healing, and higher patient compliance.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147942954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Innovations in Rheumatoid Arthritis: From Pathogenesis to Clinical Trials, Patents, and Management.","authors":"Vijay Raghav, Shweta Kumari, Swati, Reena Badhwar, Madhuri Grover","doi":"10.2174/0115748871438297260424133143","DOIUrl":"https://doi.org/10.2174/0115748871438297260424133143","url":null,"abstract":"<p><strong>Introduction: </strong>Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disorder and one of the leading causes of disability globally. It affects approximately 1% of the population, significantly impairing quality of life and contributing to increased mortality. The disease is characterized by persistent synovial inflammation, progressive joint destruction, and extra-articular manifestations. This review aims to summarize current management insights into RA pathogenesis, and highlights significant clinical advances, and explore recent patented innovations.</p><p><strong>Methods: </strong>A comprehensive narrative review was carried out using PubMed, Google Scholar, Web of Science, ClinicalTrials.gov, and patent databases (Google patent, USPTO) to collect information on pathogenesis, treatment options, clinical trials, and RA-related patents published between 2012 and 2025. Relevance to the treatment of RA, novelty, and translational potential were important inclusion criteria.</p><p><strong>Results: </strong>The cornerstone of managing RA remains conventional and biologic therapies, while JAK inhibitors, epigenetic modulators, and cell- based therapies have recently gained attention. Clinical trials show continued research into combinational therapy approaches, predictive biomarkers, and personalized medicine. Innovation in IL-6, TNF-α, and 14-3-3 pathway targeting agents, as well as natural formulations and new diagnostic tools are also revealed by patent study.</p><p><strong>Discussion: </strong>Despite advances in disease-modifying antirheumatic drugs (DMARDs) and biologic agents, unmet needs persist, particularly in refractory cases, in biomarker identification and in the development of personalized treatment strategies. Future therapeutic development and individualized intervention strategies can benefit from the integration of new drug targets, clinical trials, and emerging patent trends.</p><p><strong>Conclusion: </strong>This review provides an updated and comprehensive understanding of RA research and development.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147943025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective Observation of Tibial Plateau Fractures Managed with Open Reduction Internal Fixation with Plate Osteosynthesis in a Tertiary Care Hospital at Chennai.","authors":"Sabari R Venkat, Ashwini Dondapati, R Ashwini, Vishal Sirohi, Priya Chaudhary, Pradeep Elangovan","doi":"10.2174/0115748871457364260314142452","DOIUrl":"https://doi.org/10.2174/0115748871457364260314142452","url":null,"abstract":"<p><strong>Background: </strong>Tibial plateau fractures account for approximately 1% of all fractures and are clinically significant due to their intra-articular features, which may compromise the long-term functionality, symmetry, and rigidity of the knee. Evaluation of the results of tibial plateau fractures treated with open reduction and internal fixation (ORIF) using plate osteosynthesis was the goal of this prospective observational study.</p><p><strong>Methods: </strong>Forty patients with closed tibial plateau fractures, aged 18 to 70, participated in a systematic prospective study conducted at Chettinad Hospital. All patients had ORIF with plate osteosynthesis. Individuals were monitored at 1, 3, and 6 months, and functional results were evaluated using the Modified Rasmussen Score.</p><p><strong>Results: </strong>In the present investigation of 40 tibial plateau fracture individuals, 87.5% were male, and the average age was 40.15 years. The most common causes (77.5%) were automobile accidents. Schatzker type VI (22.5%) and type V (20%) fractures were most common. The average surgery time was 75.9 minutes, and the average union time was 15.9 weeks. Modified Rasmussen Scores improved from 13.95 preoperatively to 25.85 after six months. Ninety-five per cent of those treated achieved satisfactory to outstanding results at final follow-up. Implant discomfort or infection occurred in 7.5% of cases. Success required restoring joint congruity, positioning, and rigidity.</p><p><strong>Discussion: </strong>Tibial-plateau fractures, a complex category of intra-articular fractures, present substantial problems owing to their complex nature and capacity for functional problems. Located in the proximal end of the tibia, these fractures represent a minor proportion of overall fractures. However, they have a disproportionately large impact, particularly in the elderly population, where they are responsible for a large number of fractures. Effective treatment of these fractures is essential to reducing long-term functional deficits and enhancing patient well-being.</p><p><strong>Conclusion: </strong>In summary, tibial plateau fractures can be effectively treated with ORIF with plates, which encourages quick healing and reduces the risk of long-term impairment.</p>.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147723586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Teeth Health in Patients with Diabetes or Cardiovascular Disease: A Current and Updated Review.","authors":"Pardis Palizban, Zahra Tolou-Ghamari","doi":"10.2174/0115748871420951251211150458","DOIUrl":"https://doi.org/10.2174/0115748871420951251211150458","url":null,"abstract":"<p><strong>Introduction: </strong>The recently published article reported that approximately 500 million individuals live with diabetes and cardiovascular disease (CVD) worldwide. It is well known that individuals with systemic diseases have a higher risk of developing dental problems. This review aims to update the association between dental problems in people with cardiovascular disease and diabetes.</p><p><strong>Methods: </strong>By searching PubMed, Web of Science, and Scopus, an evaluation of scientific texts (n=120) was conducted based on the subject of attention.</p><p><strong>Results: </strong>The strong association between periodontitis and atherosclerotic CVD suggested that patients with severe periodontitis are at an increased risk of developing CVD. In such conditions, dentists should be aware of dysfunctions associated with the saliva, which can individually increase the incidence of caries. The conditions related to the extraction sockets could be worsened due to inflammation, immune, endocrine, and neural aspects in patients with hyperglycemia. Periodontal disease is the sixth most common complication of diabetes. Diabetes mellitus is considered the most common cause of hospital admission. There is a higher chance of periodontal disease and tooth loss in patients with diabetes. Periodontitis could be associated with glycemic control.</p><p><strong>Discussion: </strong>Using subgingival instrumentation, accompanied by indigenous or total antimicrobials, and occasionally by surgical intervention to remove gum tissue when periodontitis is severe, restores glycaemic control in individuals with both periodontitis and diabetes. Oral dysbiosis could be associated with the aortic valve due to bacteria.</p><p><strong>Conclusion: </strong>Intervention and routine dental check-ups are recommended in patients with CVD and diabetes to reduce periodontal inflammation.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147676280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapeutics in Combination with Chemotherapy in Clinical Trials.","authors":"Rahaman Shaik, M Shaheer Malik, Munirah M Al-Rooqi, Shaik Azeeza, Bathurasi Mallikarjun, Varikuppala Mounika, Saleh A Ahmed","doi":"10.2174/0115748871418784251208113309","DOIUrl":"https://doi.org/10.2174/0115748871418784251208113309","url":null,"abstract":"<p><strong>Introduction: </strong>In cancer treatment, immunotherapy can be used as an adjuvant therapy in combination with chemotherapy. This review article provides a comprehensive analysis of immunotherapeutics used in combination with chemotherapy that are in clinical trials, focusing on their synergy and applications.</p><p><strong>Method: </strong>An in-depth literature search was conducted across various scientific databases, including PubMed, ClinicalTrials.gov, Scopus, and Web of Science, using relevant keywords. Both research studies and relevant data from clinical trials were thoroughly analyzed to provide a comprehensive overview of the field.</p><p><strong>Results: </strong>The analysis indicated that immunotherapy, when used as an adjunct to established chemotherapy regimens, is more effective than when used as a standalone treatment. Immunotherapeutics enhance the body's defenses against malignant cells, while chemotherapy directly targets rapidly dividing cancer cells. Moreover, interesting recent findings have suggested that certain chemotherapy agents at low doses selectively inhibit regulatory and suppressor cells, thereby enhancing the body's immune response against cancer cells.</p><p><strong>Discussion: </strong>The findings further underscore the potential synergy between chemotherapy and immunotherapy. This review delves into the concept of integrating chemotherapy and radiotherapy, which induces cell death, with immunotherapy. Specifically, emphasis is placed on ongoing clinical trials investigating immunotherapeutics in combination with chemotherapeutic agents, offering a glimpse into the future landscape of cancer treatment.</p><p><strong>Conclusion: </strong>Immuno-chemotherapeutic combinations offer an immense opportunity, as demonstrated by numerous clinical trials. In the future, a deeper understanding of their interactions and mechanisms, identifying the optimal combination, and careful assessment of clinical responses are key to successful product development.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147676316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Bumetanide in Children with Autism Spectrum Disorder: A Systematic Review and Meta-Analysis.","authors":"Ausaf Ur Rehman, Aakriti Garg, Mohd Ashif Khan","doi":"10.2174/0115748871407264251209141124","DOIUrl":"https://doi.org/10.2174/0115748871407264251209141124","url":null,"abstract":"<p><strong>Introduction: </strong>Autism Spectrum Disorder (ASD) is a neurodevelopmental condition marked by social and behavioural impairments. While behavioural therapies have progressed, pharmacological options for core symptoms remain inadequate. Bumetanide, an NKCC1 antagonist, has shown potential benefits in ASD. This systematic review and meta-analysis evaluated its efficacy and safety in children and adolescents.</p><p><strong>Methods: </strong>We searched PubMed, ScienceDirect, Scopus, and ClinicalTrials.gov until April 2024 for RCTs and observational studies involving patients with ASD aged ≤18 years. Primary outcome measures the CARS, while secondary measures include the SRS, RBS, CGI-E, and safety profiles. We conducted separate analyses for RCTs and observational studies. Risk of bias was assessed using Cochrane RoB 2.0 for RCTs and ROBINS-I for observational studies.</p><p><strong>Results: </strong>Nine studies (7 RCTs, 2 observational), comprising 952 children and adolescents aged 3-18 years, were included. At 3 months, pooled analysis of randomized trials showed a significant reduction in CARS scores with bumetanide compared with placebo (WMD = -3.11; 95% CI = -6.11 to - 0.11; p = 0.04), though heterogeneity was high (I² = 92%). At 6 months, no significant difference was observed. Bumetanide increased the risks of hypokalaemia, polyuria, diuresis, and dehydration. The overall certainty of evidence was low to very low for most outcomes.</p><p><strong>Discussion: </strong>Although bumetanide shows short-term benefits on core ASD symptoms, high heterogeneity, limited durability, and safety issues constrain its clinical applicability.</p><p><strong>Conclusion: </strong>Bumetanide may offer transient symptom improvement in ASD, but further highquality trials are warranted to establish long-term efficacy, safety, and responder profiles.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147676174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Systematic Review and Meta-Analysis of the Efficacy and Safety of Intranasal Esketamine for Rapid Symptom Relief in Treatment-resistant Depression.","authors":"Ritika Saun, Aakriti Garg, Mohd Ashif Khan","doi":"10.2174/0115748871407261251215071206","DOIUrl":"https://doi.org/10.2174/0115748871407261251215071206","url":null,"abstract":"<p><strong>Introduction: </strong>Most of the Major Depressive Disorder (MDD) patients experience Treatment-Resistant Depression (TRD), wherein standard pharmaceutical and psychological interventions fail to provide adequate symptom relief. This systematic review and meta-analysis investigated the efficacy and safety of intranasal esketamine for rapid symptom relief in adults with TRD.</p><p><strong>Material and methods: </strong>The search strategy adhered to PRISMA guidelines and included PubMed, Science Direct, and Google Scholar up to January 2024. The study focused on adults aged 18 or older with TRD. Exclusions were non-RCTs, participants under 18 years, those with recent (past 6 months) suicidal or homicidal ideation, and non-English articles. Quality assessment was done using the Risk of Bias Tool 2 (ROB2).</p><p><strong>Results: </strong>Nine RCTs were included. Esketamine plus an antidepressant produced a significant improvement in MADRS scores within 24 hours (mean difference -3.44; 95% CI -5.51 to -1.38). However, esketamine was associated with a higher incidence of adverse events, including elevated blood pressure (RR 3.10; 95% CI 2.24-4.29) and dissociation (RR 5.90; 95% CI 4.32-8.05).</p><p><strong>Discussion: </strong>These findings support intranasal esketamine as a rapidly acting intervention for TRD, consistent with emerging evidence on glutamatergic modulation. Nonetheless, short follow-up periods, heterogeneity in dosing protocols, and a notable adverse event profile limit broader generalization. Long-term safety, durability of response, and real-world tolerability remain insufficiently explored.</p><p><strong>Conclusion: </strong>Esketamine demonstrates efficacy in achieving rapid relief of depressive symptoms in TRD, but findings must be interpreted with caution, given the heterogeneity and adverse event profile. Further high-quality, long-term studies are warranted to establish sustained efficacy and safety.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147676202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison between Tightrope and Hook Plate Techniques in the Treatment of Acromioclavicular Joint Dislocations: A Systematic Review and Meta-Analysis.","authors":"Saud Nayef Salem Aldanyowi, Abdulsalam Mohammed Aleid, Yousef Khalaf A Alghamdi, Hasan Ali Abdullah AlAidarous, Zainab Mohammed Aleid","doi":"10.2174/0115748871406184251208111705","DOIUrl":"https://doi.org/10.2174/0115748871406184251208111705","url":null,"abstract":"<p><strong>Introduction: </strong>Acromioclavicular joint (ACJ) dislocations are common, particularly in athletes. Surgical treatments, including tightrope (TR) and hook plate (HP) techniques, are frequently used, yet no consensus exists on the most effective approach. This study aimed to compare TR and HP methods for managing ACJ dislocations.</p><p><strong>Methods: </strong>Following PRISMA guidelines, we conducted a systematic review of PubMed, Scopus, and Web of Science databases, including randomized controlled trials, cohort, and case-control studies. Statistical analysis was performed using RevMan software.</p><p><strong>Results: </strong>A total of 10 studies with 285 patients in the TR group and 355 in the HP group were analyzed. The TR technique showed a significant reduction in pain (MD=-0.3, p =0.04) and lower blood loss (MD=-36.14, p <0.00001) compared to the HP method. No significant differences were noted in shoulder function (Constant-Murley score: MD=-0.14, p =0.95), joint stability (coracoclavicular distance: MD=0.47, p =0.41), or patient satisfaction (ASES: MD=-2.28, p =0.67).</p><p><strong>Discussion: </strong>Both techniques offered similar functional and stability outcomes, yet TR presented clear benefits in pain management and reduced blood loss. These advantages suggest that TR may be a better option for minimizing complications and improving recovery. The comparable results in shoulder function and stability implied that surgeon preference and patient-specific factors should guide the choice of technique.</p><p><strong>Conclusion: </strong>TR provided superior pain relief, less intraoperative blood loss, and fewer implantrelated complications compared to HP, while both methods offered similar outcomes in functional recovery and satisfaction.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148259556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}